Pay in 4 interest-free payments of $10.50 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
123(26):4111-9
compared with bortezomib
LLY-507 was used at 10 µM final concentration in various in vitro assays
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth
2015 Dec 9
TRX-818 - CAS# 1256037-58-7 039 123(26):4111-9TRX 818, also known as Foslinanib, CVM 1118, CAS No. 1256037 58 7, is an orally bioavailable agent with potential antineoplastic and anti vasculogenic mimicry (VM) activities. Although the exact multiple mechanisms of action through which this agent exerts its effects have yet to be fully elucidated, TRX 818, upon oral administration appears to induce cancer cell apoptosis and inhibits cancer cell proliferation. This agent also prevents tumor cell VM
US$ 69.90
US$ 68.90
US$ 10.00
US$ 449.50
US$ 10.00
US$ 169.00
US$ 18.90
US$ 124.00
US$ 10.96
US$ 11.81
US$ 159.99